CEP
EGRX

Chicago Equity Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Chicago Equity Partners’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-14,135
Closed -$849K – 897
2019
Q4 		$849K Sell
14,135
-21,740
-61% -$1.3M 0.05% 508
2019
Q3 		$2.03M Buy
35,875
+20,075
+127% +$1.13M 0.1% 312
2019
Q2 		$880K Buy
+15,800
New +$824K 0.04% 557

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Chicago Equity Partners's EGRX Position: Q1 2020 in Review

Chicago Equity Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2020, closing a stake of 14,135 shares — an estimated $849K sold.

Chicago Equity Partners first reported a position in EGRX in Q2 2019 and held it in 3 quarters. The position peaked at $2.03M in Q3 2019. 168 funds tracked by Wall St. Rank hold EGRX as of Q1 2020.

  • Chicago Equity Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • Chicago Equity Partners sold 14,135 Eagle Pharmaceuticals, Inc. shares in Q1 2020, an estimated $849K.
  • Chicago Equity Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2019 and held it in 3 quarters.
  • Chicago Equity Partners's Eagle Pharmaceuticals, Inc. position peaked at $2.03M in Q3 2019.
  • 168 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.